

## No evidence of progressive pro-inflammatory cytokine storm in brain dead organ donors - A time course analysis using clinical samples

Kasia D Bera<sup>1,3</sup>, Joel Tabak<sup>2</sup>, Rutger J Ploeg<sup>1,3</sup>

- 1- Oxford Transplant Centre, Nuffield Department of Surgical Sciences, Oxford, UK
- 2- Institute of Biological and Clinical Science, University of Exeter Medical School, Exeter UK
- 3- Oxford University NHS Foundation Trust, Oxford, UK

### Corresponding author:

KD Bera, [bera@doctors.org.uk](mailto:bera@doctors.org.uk)

### ORCID ID

**KD Bera** 0000-0003-3795-6762

**J Tabak** 0000-0002-0588-957X

**RJ Ploeg** 0000-0001-7801-665X

### List of abbreviations

BMI	Body Mass Index
C5a	Complement component 5a
DBD	Donation after brain death
DCD	Donation after circulatory death
DGF	Delayed graft function
DM	Diabetes Mellitus
eGFR	Estimated Glomerular Filtration Rate
GFAP	Glial Fibrillary Acidic Protein
Hsp70	Heat Shock Protein 70
HO-1	Heme Oxygenase 1
ICH	Intracranial haemorrhage
IL-6	Interleukin 6
NSE	Neuron Specific Enolase
QUOD	Quality in Organ Donation
TNF-alpha	Tumour Necrosis Factor alpha

1    **Abstract**

2    Organ donation after brain death (DBD) is an important source of transplanted organs as  
3    chronic undersupply means many patients die whilst awaiting a transplant. Improving organ  
4    quality and graft survival is key to reducing waiting lists. The interval between brain death  
5    confirmation and organ procurement offers an opportunity to reduce organ injury or  
6    encourage repair, yet data is lacking on the effects of brain injury on future grafts and which  
7    pathways to target. In fact, the consensus view has been that brain death exposes organs to  
8    a progressively pro-inflammatory environment, suggesting organ procurement must occur  
9    within a limited time window. Here, we developed a novel method of studying time-course  
10   changes in serum proteins in a DBD cohort from a UK biobank. Individual donor trajectories  
11   were combined to determine the time course of pro-inflammatory (Tumour Necrosis Factor  
12   alpha, Interleukin 6, Complement) mediators and markers of central nervous injury (Neuron  
13   Specific Enolase, Glial Fibrillary Acidic Protein) after confirmation of brain death. We found  
14   no evidence of a rise of TNF-alpha, NSE, IL-6 or C5a with prolonged duration of brain death,  
15   questioning the consensus view of progressively pro-inflammatory environment. We also  
16   identified complement as a potential target for therapeutic intervention to improve organ  
17   quality.

18

19

20

21

22

## 23 1. Introduction

24 Organ transplantation is a lifesaving and cost-effective treatment for patients with end-stage organ  
25 failure; however, donor organ shortages mean many patients still die whilst awaiting a transplant. In  
26 addition, many procured older and higher risk donor organs are considered un-transplantable,  
27 declined by transplant centres and thus not utilised. It is therefore imperative that we improve  
28 organ quality as well as maintaining good long-term transplant survival. Donation after brain death  
29 (DBD) is the most common source of deceased donor organs worldwide. Whilst DBD offers a more  
30 controlled environment than procuring organs after circulatory death (when donors will have  
31 suffered from a respiratory and cardiac arrest) long term outcomes between both types of donation  
32 remain comparable<sup>1,2</sup>. Historically, the events surrounding brain death have been described as  
33 ‘hostile’ including a catecholamine storm with significant haemodynamic, metabolic and hormonal  
34 changes as well as a progressive release of pro-inflammatory mediators (e.g Tumour necrosis Factor  
35 (TNF) -alpha and Interleukin (IL)-6) and activation of the complement cascade. Chemokine exposure  
36 contributes to the long-term trajectory of an organ, leading to fibrosis, impacting on long-term  
37 function and ultimately reducing graft survival<sup>3-5</sup>.

38  
39 To minimise the duration of grafts-to-be in a presumed hostile environment, rapid procurement of  
40 organs was adopted. Retrospective analyses, however, demonstrate that longer duration of organ  
41 donor management in critical care actually may be beneficial for some of the transplanted organs,  
42 reducing rate of delayed graft function (DGF) for renal allografts from younger donors and without  
43 negative impact on transplanted liver or pancreas<sup>6,7</sup>. The period of brain dead organ donor  
44 management in critical care also offers a therapeutic window of intervention, yet our understanding  
45 of inflammatory processes during this period remains limited. Management of the brain dead donor  
46 has evolved and improved in recent history: for example, in the UK a ‘donor care bundle’ used by  
47 intensivists provides guidance and donors universally receive corticosteroids<sup>8</sup>, yet detailed  
48 knowledge of how this impacts the pro- and anti-inflammatory balance is currently lacking. Animal

49 models of brain death have been limited to a short time frame (4-6 hours)<sup>9-12</sup>. Prior studies of  
50 inflammatory serum changes in DBD organ donors measured only a limited number of time points  
51 and/or study donors with heterogenous pathologies that result in brain death<sup>13-18</sup>. Understanding  
52 details of the time course surrounding brain death is key to developing strategies to reduce organ  
53 injury or promote repair, but detailed translation from preclinical studies is lacking and availability of  
54 clinical samples is limited.

55

56 We hypothesised that the selection of a donor cohort with a common underlying pathology would  
57 enable us to determine the temporal changes of biomarkers of brain injury (NSE, GFAP – to reflect  
58 neuronal and glial injury, respectively) and pro-inflammatory mediators (TNF- $\alpha$ , IL-6 and  
59 complement), from confirmation of brain death through to organ procurement. Understanding the  
60 time course can be then used to identify target pathways for treatment even before organ  
61 procurement to improve long term organ quality and graft survival.

62

## 63 **2. Methods**

### 64 **2.1 Donor cohort and serum sample selection process**

65 Serum samples from the UK Quality in Organ Donation (QUOD) biobank were selected to study the  
66 brain death period between 10 and 30 hours (from confirmation of brain death by completed  
67 second brain stem test through to organ procurement). Inclusion criteria used were: presence of  
68 valid consent; availability of three serum samples (before brain death; after confirmation of brain  
69 death, at end of donor management period); intracranial haemorrhage (ICH) as cause leading to  
70 brain death, as well as the documented duration of brain death. The following exclusion criteria  
71 were used: incomplete set of serum samples; other causes of brain death (such as but not limited to  
72 hypoxic brain injury, trauma, ischaemia, infection); documented systemic source of elevated  
73 inflammatory markers (trauma, documented infection such as e.g. pneumonia or urinary infection).

74

75 To allow selection of donors who were similar in characteristics other than the duration of brain  
76 death, the 20-hour period was broken down into four 5-hour blocks (10-15 hours, 15-20 hours, 20-  
77 25 hours, 25-30 hours of brain death) and for each block, donors were selected to be balanced for  
78 age, gender, body mass index, co-morbidities (especially hypertension and diabetes), duration of  
79 cold ischemia time and renal function after transplantation. The inclusion of the latter two ensured  
80 that the selection of donors was not biased to those with known factors associated with particularly  
81 good or bad post-transplant outcomes. In addition, donors who fulfilled all inclusion criteria but had  
82 documented 'extremes' of brain death (< 10h or > 30h) were also included to allow study of time  
83 course either side of the core time frame.

84

85 The final cohort included n=27 donors. All included donors had a complete set of serum samples,  
86 however for six donors the exact time point of the first sample collection at time of admission was  
87 not documented; the time and date of admission recorded by NHSBT was used instead. These  
88 donors with one missing time point were evenly distributed between the brain death groups. The  
89 QUOD programme research approval as a Research Tissue Bank (REC ref 13/NW/0017, from North  
90 West - Greater Manchester Central Research Ethics Committee,) covers the provision of data and  
91 research samples for research into improving the quality of organ quality for transplantation.

92

## 93 **2.2 Enzyme linked immune absorption assay (ELISA)**

94 All received samples were stored at -80C before use. DuoSet® ELISA Kits (R&D Systems) for human  
95 IL-6, TNF-alpha, Complement 5a, NSE and GFAP were used according to the manufacturer's  
96 instructions. Each sample was measured in duplicates using a Bio-Rad iMark™ Microplate Reader.  
97 MatLab and GraphPad Prism9 were used for data analysis. The mean value from the duplicate  
98 measurements (followed by transformation using  $\ln(Y+1)$ ) was used for the time course plots (Fig 1).

99

100

### 101 **2.3 Moving median analysis**

102 Before combined analysis of donor serum levels, the Robust regression and Outlier removal (ROUT)  
103 method was used to identify outliers. Donors for which at least four outliers out of the five  
104 measured serum molecules were excluded before a moving median was calculated. This analysis  
105 removed three donors – one from the 25-30h brain death duration group and two from the >30h  
106 brain death group, representing the oldest donors in this group, one with a missing admission time  
107 point.

108

109 Subsequently, data for all remaining donors was combined using moving median plots for each  
110 serum level of the molecules. In detail, the time of brain death confirmation was defined as  $t = 0$  for  
111 each donor. Thus, for each patient and each marker, we have a set of three sample measurements,  
112 one before brain death, one at brain death ( $t = 0$ ), and one after brain death. Because the sample  
113 before and after brain death were obtained at different times for the different patients, the  
114 ensemble of measurements across patients contain information about marker time course before  
115 and after brain death. We did not directly combine all the measurements into one time course for  
116 each marker, as this would make the strong assumption that markers from different patients follow  
117 an identical time course. Here, we make a softer assumption that the time courses from different  
118 patients follow qualitatively *similar* trajectories. Following that assumption, we can combine  
119 measurements from different patients using a moving median of the time points, as long as the  
120 window is large enough to account for the variability across patients.

121

122 We constructed a moving median for the 20-hour period before confirmation of brain death, and  
123 the 40-hour period following brain death. For the 20-hour period before confirmation of brain  
124 death, we replaced each level by the median of all levels within a 20-hour window centred on that  
125 point and sampled before  $t = 0$ . Similarly, for the 40-hour period of time after confirmation brain

126 death, we used a 20-hour moving window using only levels sampled after  $t = 0$ . For  $t = 0$ , the median  
127 of all samples collected at this clinical time point was used.

### 128 **3. Results**

#### 129 **3.1 Selection of study cohort: DBD donors with different durations of brain death**

130 The Quality in Organ Donation (QUOD) biobank contains samples from over 85% of all deceased  
131 organ donors in the UK, alongside detailed clinical donor and recipient information<sup>19</sup>. Samples,  
132 including serum and urine, are collected at clinically pre-defined time points: admission (DB1),  
133 confirmation of brain death (DB2), end of donor management (DB3), and immediately prior to  
134 removal of the donor organs (DB4). As most DBD organ donors in the UK have suffered a non-  
135 survivable ICH, the selection of donors was limited to this pathology. Our selection criteria identified  
136 donors with varying duration of brain death, as defined by period from confirmation of brain death  
137 to end of organ donor management but before organ procurement. This created a cohort that  
138 included durations of brain death ranging from 10 to 30 hours. At the point of study design, the  
139 QUOD biobank included 268 DBD with a complete set of three serum samples (DB1-3); of those, 51  
140 donors had ICH as the documented cause of brain death, and 45/51 donors (88.23%) had a  
141 documented brain death duration between 10 and 30 hours (mean 19.3 +/- 7 hours). We  
142 subsequently excluded donors with a history of other sources of inflammation. To further define the  
143 final study cohort, 5-hour windows of brain death duration were defined with five donors per group;  
144 within each group, donors were selected to be matched for factors such as body mass index, sex,  
145 and age. Two additional groups of donors with 'extremes' of duration of brain death were included:  
146 'short BD' (<10 hours) with 2 donors and 'long BD' (>30 hours) with 5 donors. This resulted in n=27  
147 selected donors for the final cohort. Characteristics of all included donors are displayed in Table 1.  
148 One-way ANOVA was used to evaluate the balance between the groups regarding the specified  
149 continuous parameters and confirm matched creation of study cohort. When the two extremes of  
150 BD groups are included, donor age was statistically different between all groups, with notable anti-  
151 correlation between donor age and brain death duration ( $p = 0.0017$ ,  $R^2 = 0.33$ ). This likely reflects

152 underlying decision making: e.g., for younger donors a prolonged duration of BD might be deemed  
153 acceptable, whilst organs from older donors might be accepted when cold ischaemia time and  
154 transport duration can be minimised.

### 155 **3.2 Creation of time course analysis**

156 Serum levels of IL-6, TNF- $\alpha$ , C5a, NSE and GFAP were recorded at time points of admission (sample  
157 DB1), after confirmation of brain death (sample DB2), and at the end of organ donor management  
158 (sample DB3) (Fig. 1A). As each sample was taken at a clinically defined time point, comparison was  
159 only possible by setting the sample taken after confirmation of brain death as  $t=0$ . The timeline was  
160 divided into the period of ICH management prior to confirmation of brain death ( $t<0$ ) and a period of  
161 organ donor management ( $t>0$ ) after brain death was confirmed. A direct comparison to prior  
162 studies of biomarkers of brain injury and pro-inflammatory mediators is not straightforward due to  
163 heterogeneity of underlying pathologies (traumatic brain injury, ischaemic or haemorrhagic stroke,  
164 brain injury following cardiac arrest) as well as selection of different time points in a dynamic and  
165 evolving situation across studies (see Supplementary Table<sup>20-28</sup>).

166

167 The described selection process of donors with similar backgrounds and identical pathologies aimed  
168 to reduce heterogeneity to create a study cohort. In addition, prospective rules were agreed to  
169 identify outliers which were then excluded before undertaking a time course analysis (see Methods).

170 This resulted in the exclusion of three donors with outlying results for at least 4 of the 5 studied  
171 biomarkers. Two of the excluded donors were in the (additional) “long BD” group. Individual donor  
172 trajectories for the remaining 24 donors broken down by IL-6, TNF- $\alpha$ , C5a, NSE and GFAP are shown  
173 in Figure 1B.

174

175 Each donor has a unique duration of brain death before organ procurement, but combining the  
176 information from all 24 donor samples into a ‘moving median’ allowed us to ascertain an underlying  
177 time course. Figure 1C demonstrates the moving median with a window size of 20 hours for each of



178 the serum markers from 20 hours prior to t=0 to 40 hours after confirmation of brain death. The  
179 moving median delineates a time course for each measured serum marker over time. The pro-  
180 inflammatory cytokines IL-6 and TNF- $\alpha$  do *not* follow a time course that would indicate a  
181 progressively hostile environment; TNF- $\alpha$  levels in serum decline from admission to end of donor  
182 management and IL-6 demonstrates a broad peak around confirmation of brain death, with  
183 subsequently decline. NSE (released from damaged neurons) and the complement cascade  
184 component C5a both remain elevated from patient admission through confirmation of brain death  
185 to end of donor management. GFAP, indicating glial cell breakdown, demonstrates a step-like time  
186 course reaching plateau over the donor management period. Donor brain death is believed to occur  
187 as a result of irreversible damage to the brain stem secondary to oedema and ultimately brain stem  
188 herniation<sup>29</sup>; Our findings suggest that whilst neuronal damage leads to a steady level of released  
189 NSE from admission onwards, there is a step change in glial breakdown products (detected in  
190 serum) around the time of confirmation of brain death reflective of larger volume glial injury.

191

#### 192 **4. Discussion**

193 Organs from brain dead donors underperform in the long term and only function at a level  
194 comparable to organs obtained from donors after circulatory death<sup>1</sup>; DCD kidneys, for example,  
195 experience a higher rate of delayed graft function (DGF), however – if DGF remains brief - this does  
196 not translate into worse long-term recipient or graft survival<sup>30</sup>. Following confirmation of brain death  
197 whilst patients remain in critical care units, there is a logistical lag until organ procurement, we are  
198 therefore offered a window of opportunity to optimise donors further and improve organ function  
199 or reduce damage. In 2017/18 in the UK, there were on average 21 hours 48 minutes between the  
200 discussion with the donor's family and start of the procurement<sup>31</sup>. In the USA, longer donor  
201 management times are reported, which is likely a reflection of different geographical and logistical  
202 solutions to the procurement and transportation of donor organs<sup>32</sup>. Our study offers a first  
203 characterisation of the serum changes during the duration of donor management in UK critical care

204 units, reporting alterations in key pro-inflammatory mediators as well as markers of central nervous  
205 system injury that are not usually present in human serum or plasma in the absence of injury<sup>33</sup>. The  
206 time courses of the different biomarkers obtained by combining individual donor trajectories  
207 challenge the current consensus of a progressively pro-inflammatory environment, -- the so-called  
208 cytokine storm, -- after brain death.

209 Our work has several strengths such as the use of high-quality clinical samples from a UK biobank  
210 with a high consent rate (>85% of all DBD donors), thus a very good representation of the overall  
211 organ donor population. Careful matching of donors, and exclusion of those where other factors  
212 could affect inflammatory markers (such as due to trauma, anoxia or infection), allowed us to infer  
213 the time-course in the 'most typical DBD donor': an isolated intracranial haemorrhage as cause for  
214 brain death. The samples that form QUOD biobank are collected based on clinical events, such as  
215 confirmation of brain death after brain stem testing, rather than set time points; this is of benefit in  
216 a situation where we do not understand the underlying time course.

217 The study has also limitations. Firstly, the final study cohort that allowed for matched characteristics  
218 was small (24 donors). This was due to the limited availability of a admission (DB1) sample, only  
219 present in around 10% of all QUOD DBD samples. Our experimental design excluded patients where  
220 pathology preceding brain death would have been likely to produce systemic or neuroinflammation  
221 (e.g. traumatic brain injury) or are likely to differ in pathology (e.g. hypoxia), as these could  
222 confound the results. It is likely that brain-death related molecular changes follow different  
223 trajectories when brain death occurs as a consequence of global hypoxia rather than intracranial  
224 haemorrhage. Finally, it should be noted that our goal was to understand changes representing  
225 serum levels of pro-inflammatory markers present in the donor and thus impacting the transplants-  
226 to-be, rather than detailed kinetic analysis including release or breakdown of molecules. Additionally  
227 the study was not designed to compare individual organ outcomes and did not include a comparison

228 of groups with known 'good' vs. 'bad' post-transplantation outcomes, such as e.g. eGFR after 12  
229 months.

230 This is the first time-course analysis of serum TNF-alpha, IL-6 and C5a in human DBD donors  
231 surrounding the donor care up to organ procurement. Serum changes of NSE and GFAP provide  
232 insights into the intracranial pathology with increasing release of proteins indicating progressive glial  
233 damage around confirmation of brain death.

234 Ultimately, however, the next steps are to build on our findings to determine how to improve organ  
235 quality and post-transplant outcomes. Legally and ethically, treatments to any donor aiming to  
236 improve transplantation outcomes can only be administered *after* brain death is confirmed.  
237 Therefore, understanding which pathways are amenable to intervention during this time frame is  
238 paramount. Targeting pathways or molecules that are already low or declining - whether due to the  
239 treatments provided in critical care or as part of a response to the initial injury - would be futile and  
240 likely not translate into meaningful results. Our work suggests that IL-6 or complement should be  
241 considered feasible targets for intervention during donor management. Recent animal work  
242 confirms a plateau of serum IL-6 and decline of TNF-alpha after intracranial hypertension is  
243 experimentally induced.<sup>34</sup> Apart from inhibiting pro-inflammatory mediators, induction of anti-  
244 inflammatory pathways might offer alternative avenues: Histological studies of donated DBD  
245 kidneys report expression of protective, anti-inflammatory heat shock proteins (Hsp70, HO-1)  
246 alongside known pro-inflammatory mediators – with anti-inflammatory upregulation translating into  
247 protecting or restoring renal function<sup>35</sup>. Both strategies could lead to reduction or elimination of  
248 long-term fibrotic changes known to be linked to e.g. macrophage polarisation and complement  
249 mediated renal inflammation.<sup>5,18</sup>

250 Importantly, our study did not provide evidence which supports the previously upheld cytokine  
251 storm theory that underpins the perceived need to procure organs as quickly as possible. A recent

252 UNOS study of cardiac transplantation showed that longer (>42 hours) brain death times did not  
253 result in worse outcomes<sup>36</sup>. A study from Israel found no correlation between duration of brain  
254 death and adverse outcomes in cardiac transplantation, although short duration of brain death was  
255 defined as shorter than 97 hours<sup>37</sup>. Our results have possible implications for further work to identify  
256 optimal procurement time points.

257 Finally, we believe our work translates more widely by proposing a novel approach how human  
258 samples collected e.g. as part of a biobank can be used to study time courses directly in humans and  
259 guide identification of treatment targets and timings. By creating a 'meta-cohort' from post hoc data,  
260 our modelling approach allowed us to use limited clinical samples to study the time-course of  
261 various biomarkers leading up to organ donation. Development of new therapies typically relies  
262 upon pre-clinical animal models. However, in cases where the underlying biology is poorly  
263 understood, human pathophysiology differs or no appropriate models exist, alternative methods are  
264 required. Our approach allows to study serum changes surrounding key events using human samples  
265 and can be translated to other clinical settings where repeat sampling is difficult, not possible or  
266 unethical.

267

268

269 **Acknowledgments**

270 KDB was supported by the National Institute for Health Research (NIHR) with an NIHR Academic  
271 Clinical Fellowship. KDB received a pump priming research grant from the Oxford Transplant  
272 Foundation to support this project (R56956/AA001)

273

274 The authors would like to thank Dr Sergei Maslau for his help with the initial selection of the study  
275 cohort and Dr Michael Craig for his thoughts and comments on earlier versions of the manuscript.  
276 We would like to thank all organ donors and their families – none of this work would be possible  
277 without them. This study was made possible by obtaining samples and data from the UK QUOD  
278 Biobank which is a partnership programme between UK academic transplant centres and NHS Blood  
279 and Transplant.

280

281 **Disclosures of interest**

282 RJP is the Principal Investigator for the Quality in Organ Donation (QUOD) programme  
283 KDB was supported by the National Institute for Health Research (NIHR) with an NIHR Academic  
284 Clinical Fellowship. KDB received a pump priming research grant from the Oxford Transplant  
285 Foundation to support this project (R56956/AA001)

286 The remaining author has no conflicts of interest to disclose

287

288 **References**

- 289 1. Gagandeep S, Matsuoka L, Mateo R, et al. Expanding the donor kidney pool: utility of renal  
290 allografts procured in a setting of uncontrolled cardiac death. *Am J Transplant*. 2006;6(7):1682-  
291 1688. doi:10.1111/j.1600-6143.2006.01386.x
- 292 2. Müller AK, Breuer E, Hübel K, et al. Long-term outcomes of transplant kidneys donated after  
293 circulatory death. *Nephrol Dial Transplant*. Published online December 17, 2021:gfab358.  
294 doi:10.1093/ndt/gfab358
- 295 3. Torres IB, Moreso F, Sarró E, Meseguer A, Serón D. The Interplay between Inflammation and  
296 Fibrosis in Kidney Transplantation. *Biomed Res Int*. 2014;2014:750602.  
297 doi:10.1155/2014/750602
- 298 4. Miller CL, Madsen JC. IL-6 Directed Therapy in Transplantation. *Curr Transplant Rep*. Published  
299 online June 3, 2021:1-14. doi:10.1007/s40472-021-00331-4
- 300 5. Ordikhani F, Pothula V, Sanchez-Tarjuelo R, Jordan S, Ochando J. Macrophages in Organ  
301 Transplantation. *Frontiers in Immunology*. 2020;11. doi:10.3389/fimmu.2020.582939
- 302 6. Boffa C, Curnow E, Martin K, et al. The Impact of Duration of Brain Death on Outcomes in  
303 Abdominal Organ Transplantation: Rush and Retrieve or Relax and Repair 2017? A Retrospective  
304 UK Transplant Registry Analysis. *Transplantation*. 2017;101:S1.  
305 doi:10.1097/01.tp.0000524966.72734.fb
- 306 7. Nijboer WN, Moers C, Leuvenink HGD, Ploeg RJ. How important is the duration of the brain  
307 death period for the outcome in kidney transplantation? *Transplant International*.  
308 2011;24(1):14-20. doi:10.1111/j.1432-2277.2010.01150.x

- 309 8. NHS Blood and Transplant. *Donation after Brainstem Death (DBD) Donor Optimisation Extended*  
310 *Care Bundle*. Accessed March 27, 2021. [http://odt.nhs.uk/pdf/dbd\\_care\\_bundle.pdf](http://odt.nhs.uk/pdf/dbd_care_bundle.pdf)
- 311 9. Koudstaal LG, 't Hart NA, Ottens PJ, et al. Brain death induces inflammation in the donor  
312 intestine. *Transplantation*. 2008;86(1):148-154. doi:10.1097/TP.0b013e31817ba53a
- 313 10. Kolkert JLP, 't Hart NA, van Dijk A, Ottens PJ, Ploeg RJ, Leuvenink HGD. The gradual onset brain  
314 death model: a relevant model to study organ donation and its consequences on the outcome  
315 after transplantation. *Lab Anim*. 2007;41(3):363-371. doi:10.1258/002367707781282848
- 316 11. Saito Y, Goto M, Maya K, et al. The Influence of Brain Death on Tissue Factor Expression in the  
317 Pancreatic Tissues and Isolated Islets in Rats. *Transplantation Proceedings*. 2009;41(1):307-310.  
318 doi:10.1016/j.transproceed.2008.10.080
- 319 12. Contreras JL, Eckstein C, Smyth CA, et al. Brain death significantly reduces isolated pancreatic  
320 islet yields and functionality in vitro and in vivo after transplantation in rats. *Diabetes*.  
321 2003;52(12):2935-2942. doi:10.2337/diabetes.52.12.2935
- 322 13. Lopau K, Mark J, Schramm L, Heidbreder E, Wanner C. Hormonal changes in brain death and  
323 immune activation in the donor. *Transpl Int*. 2000;13 Suppl 1:S282-285.  
324 doi:10.1007/s001470050342
- 325 14. Amado JA, López-Espadas F, Vázquez-Barquero A, et al. Blood levels of cytokines in brain-dead  
326 patients: relationship with circulating hormones and acute-phase reactants. *Metabolism*.  
327 1995;44(6):812-816. doi:10.1016/0026-0495(95)90198-1
- 328 15. Stangl M, Zerkaulen T, Theodorakis J, et al. Influence of brain death on cytokine release in organ  
329 donors and renal transplants. *Transplant Proc*. 2001;33(1-2):1284-1285. doi:10.1016/s0041-  
330 1345(00)02479-9

- 331 16. Schwarz P, Custódio G, Rheinheimer J, Crispim D, Leitão CB, Rech TH. Brain Death-Induced  
332 Inflammatory Activity is Similar to Sepsis-Induced Cytokine Release. *Cell Transplant*.  
333 2018;27(10):1417-1424. doi:10.1177/0963689718785629
- 334 17. Murugan R, R V, As W, et al. Increased plasma interleukin-6 in donors is associated with lower  
335 recipient hospital-free survival after cadaveric organ transplantation. *Crit Care Med*.  
336 2008;36(6):1810-1816. doi:10.1097/ccm.0b013e318174d89f
- 337 18. Werkhoven MB van, Damman J, Dijk MCRF van, et al. Complement Mediated Renal  
338 Inflammation Induced by Donor Brain Death: Role of Renal C5a-C5aR Interaction. *American*  
339 *Journal of Transplantation*. 2013;13(4):875-882. doi:10.1111/ajt.12130
- 340 19. QUOD. Quality in Organ Donation website. QUOD. Accessed February 5, 2022.  
341 <https://quod.org.uk/for-researchers/>
- 342 20. Vos PE, Lamers KJB, Hendriks JCM, et al. Glial and neuronal proteins in serum predict outcome  
343 after severe traumatic brain injury. *Neurology*. 2004;62(8):1303-1310.  
344 doi:10.1212/01.WNL.0000120550.00643.DC
- 345 21. Lei J, Gao G, Feng J, et al. Glial fibrillary acidic protein as a biomarker in severe traumatic brain  
346 injury patients: a prospective cohort study. *Crit Care*. 2015;19(1):362. doi:10.1186/s13054-015-  
347 1081-8
- 348 22. El-Maraghi S, Yehia H, Hossam H, Yehia A, Mowafy H. The prognostic value of neuron specific  
349 enolase in head injury. *The Egyptian Journal of Critical Care Medicine*. 2013;1(1):25-32.  
350 doi:10.1016/j.ejccm.2012.12.002
- 351 23. Antunes AA, Sotomaior VS, Sakamoto KS, de Camargo Neto CP, Martins C, Aguiar LR. Interleukin-  
352 6 Plasmatic Levels in Patients with Head Trauma and Intracerebral Hemorrhage. *Asian J*  
353 *Neurosurg*. 2010;5(1):68-77.



- 354 24. Hergenroeder GW, Moore AN, McCoy JP, et al. Serum IL-6: a candidate biomarker for  
355 intracranial pressure elevation following isolated traumatic brain injury. *J Neuroinflammation*.  
356 2010;7(1):19. doi:10.1186/1742-2094-7-19
- 357 25. Moseby-Knappe M, Mattsson-Carlgrén N, Stammet P, et al. Serum markers of brain injury can  
358 predict good neurological outcome after out-of-hospital cardiac arrest. *Intensive Care Med*.  
359 Published online August 21, 2021. doi:10.1007/s00134-021-06481-4
- 360 26. Mocco J, Wilson DA, Komotar RJ, et al. Alterations in plasma complement levels after human  
361 ischemic stroke. *Neurosurgery*. 2006;59(1):28-33; discussion 28-33.  
362 doi:10.1227/01.NEU.0000219221.14280.65
- 363 27. Mack WJ, Ducruet AF, Hickman ZL, et al. Early plasma complement C3a levels correlate with  
364 functional outcome after aneurysmal subarachnoid hemorrhage. *Neurosurgery*. 2007;61(2):255-  
365 260; discussion 260-261. doi:10.1227/01.NEU.0000255518.96837.8E
- 366 28. Stein DM, Lindell A, Murdock KR, et al. Relationship of Serum and Cerebrospinal Fluid  
367 Biomarkers With Intracranial Hypertension and Cerebral Hypoperfusion After Severe Traumatic  
368 Brain Injury. *Journal of Trauma and Acute Care Surgery*. 2011;70(5):1096-1103.  
369 doi:10.1097/TA.0b013e318216930d
- 370 29. Ujihira N, Hashizume Y, Takahashi A. A clinico-neuropathological study on brain death. *Nagoya J*  
371 *Med Sci*. 1993;56(1-4):89-99.
- 372 30. Phillips BL, Ibrahim M, Greenhall GHB, Mumford L, Dorling A, Callaghan CJ. Effect of delayed  
373 graft function on longer-term outcomes after kidney transplantation from donation after  
374 circulatory death donors in the United Kingdom: A national cohort study. *American Journal of*  
375 *Transplantation*. 2021;21(10):3346-3355. doi:10.1111/ajt.16574

- 376 31. Curtis R, Johnson R, Gardiner D, Mumford L, McGowan O. The length of the deceased organ  
377 donation and transplantation process. Presented at: September 2019; ESOT Congress.  
378 <https://www.odt.nhs.uk/statistics-and-reports/slides-and-presentations/>
- 379 32. Jawitz OK, Raman V, Barac Y, et al. Time from Lung Transplant Donor Brain Death to Cross  
380 Clamp: An Analysis of the UNOS Registry. *The Journal of Heart and Lung Transplantation*.  
381 2019;38(4):S190. doi:10.1016/j.healun.2019.01.459
- 382 33. Huebschmann NA, Luoto TM, Karr JE, et al. Comparing Glial Fibrillary Acidic Protein (GFAP) in  
383 Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults. *Frontiers in Neurology*.  
384 2020;11:1054. doi:10.3389/fneur.2020.01054
- 385 34. do Espírito Santo MP, Faria CS, Solla DJF, et al. Inflammatory markers assessment in an animal  
386 model of intracranial hypertension: a randomized trial. *Intensive Care Med Exp*. 2021;9:42.  
387 doi:10.1186/s40635-021-00408-5
- 388 35. Nijboer WN, Schuurs TA, van der Hoeven JAB, et al. Effects of brain death on stress and  
389 inflammatory response in the human donor kidney. *Transplantation Proceedings*.  
390 2005;37(1):367-369. doi:10.1016/j.transproceed.2004.12.262
- 391 36. Jawitz OK, Raman V, Barac YD, et al. Influence of donor brain death duration on outcomes  
392 following heart transplantation: A United Network for Organ Sharing Registry analysis. *The*  
393 *Journal of Thoracic and Cardiovascular Surgery*. 2020;159(4):1345-1353.e2.  
394 doi:10.1016/j.jtcvs.2019.04.060
- 395 37. Kogan A, Ram E, Nachum E, Kassif Y, Lavee J, Peled Y. Does duration of donor brain injury impact  
396 heart transplantation outcomes? *Clinical Transplantation*. 2019;33(8):e13660.  
397 doi:<https://doi.org/10.1111/ctr.13660>
- 398



400 **Figure legend**

401 **Figure 1. Serum time course analysis.** Each row represents serum levels for one of the  
402 studied biomarkers: Tumour Necrosis Factor alpha (TNF $\alpha$ ), Interleukin-6 (IL-6), Complement  
403 C5a, Glial Fibrillary Acidic Protein (GFAP) and Neuronal Specific Enolase (NSE), all levels  
404 shown in ln(y+1). For each donor, three samples based on clinically defined time points  
405 (DB1, DB2, D3) were measured, DB2 was set as t=0 to allow comparison. Panels A, B, C  
406 show analysis of serum levels from individual sample levels to combined time course  
407 analysis. (A) Comparison of serum levels of the whole donor cohort, each donor in  
408 different colour. (B) donor trajectories of final donor cohort (connecting lines depict  
409 individual donor trajectories). (C) calculated moving median to demonstrate time course for  
410 each biomarker (moving median window of 20 hours).

411

412

413

414 **Table 1.** Clinical characteristics of final study cohort.




415

	donor						recipient			
Group	Brain death (h)	Age	BMI	HTN	DM	Creatinine <sup>1</sup>	Cold ischemia time (h)	Age	BMI	eGFR at 12 months
<b>1</b> <b>&lt;10h</b>	5.9 +/- 4.0	73 +/- 8.3	31.7 +/- 0.5	2/2 HTN	1/2 DM	85.0 +/- 8.4	14.1 +/- 0.7	67.5 +/- 0.7	24.1 +/- 0.6	49.5 +/- 33.9
<b>2</b> <b>10-15h</b>	13.1 +/- 1.9	51.4 +/- 11.3	24.8 +/- 2.7	0/5 HTN	0/5 DM	62.4 +/- 9.8	13.6 +/- 5.3	51.6 +/- 16.5	22.6 +/- 5.3 <sup>3</sup>	49.2 +/- 8.5
<b>3</b> <b>15-20h</b>	17.9 +/- 1.4	53.6 +/- 6.2	31.7 +/- 6.9	3/5 HTN	1/5 DM	66.6 +/- 18.8	13.2 +/- 1.2 <sup>2</sup>	55.0 +/- 1.8	25.53 +/- 5.3 <sup>3</sup>	48.6 +/- 14.1
<b>4</b> <b>20-25h</b>	22.6 +/- 1.9	49.2 +/- 8.1	29.0 +/- 5.7	1/5 HTN	1/5 DM	59.4 +/- 24.0	18.3 +/- 6.0	47.4 +/- 19.3	26.4 +/- 5.0 <sup>2</sup>	65.4 +/- 44.7
<b>5</b> <b>25-30h</b>	26.5 +/- 1.6	48.8 +/- 10.4	25.9 +/- 3.4	1/5 HTN	1/5 DM	59.4 +/- 24.0	14.4 +/- 4.0	42.2 +/- 19.7	27.5 +/- 5.5	51.8 +/- 19.7
<b>6</b> <b>&gt;30h</b>	33.0 +/- 3.6	36.6 +/- 15.1	32.7 +/- 9.8	1/4 HTN <sup>2</sup>	1/5 DM	83.8 +/- 33.0	18.2 +/- 6.1	40. +/- 19.8 <sup>2</sup>	24.8 +/- 1.29 <sup>2</sup>	56.8 +/- 20.3
<b>P value (2-5)</b>	<0.0001	0.833	0.16			0.95	0.70	0.63	0.74	0.70
<b>P value<sup>4</sup> (1-6)</b>	<0.0001	0.015	0.28			0.45	0.42	0.37	0.72	0.89

416

417 Overview of created study cohort of n=27 donors, group 1 included 2 donors, the remaining groups included 5 donors each. The cohort was  
 418 created by selecting donors with intracranial haemorrhage (ICH), a documented length of brain death and full set of serum samples; donors

419 were matched within each 5 hour group of brain death. Extremes of post-transplantation outcome were excluded, as were donors with  
420 documented other sources of inflammatory changes such as trauma or infection. 1 at offer 2 n=1 missing data point 3 n=2 missing data points  
421 4 One way ANOVA; all shown as mean +/- SD.



1

**Figure 1. Serum time course analysis.** Each row represents serum levels for one of the studied biomarkers: Tumour Necrosis Factor alpha (TNF $\alpha$ ), Interleukin-6 (IL-6), Complement C5a, Glial Fibrillary Acidic Protein (GFAP) and Neuronal Specific Enolase (NSE), all levels shown in  $\ln(y+1)$ . For each donor, three samples based on clinically defined time points (DB1, DB2, D3) were measured, DB2 was set as  $t=0$  to allow comparison. Panels A, B, C show analysis of serum levels from individual sample levels to combined time course analysis. (A) Comparison of serum levels of the whole donor cohort, each donor in different colour. (B) donor trajectories of final donor cohort (connecting lines depict individual donor trajectories). (C) calculated moving median to demonstrate time course for each biomarker (moving median window of 20 hours).